HENDERSON, Nev. --(BUSINESS WIRE)--Jul. 29, 2020-- Spectrum Pharmaceuticals, Inc. (Nasdaq-GS: SPPI) (“Spectrum”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten registered

Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT HENDERSON, Nev. --(BUSINESS WIRE)--Jul. 27, 2020-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it met the

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 22, 2020-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced preclinical data evaluating the administration of ROLONTIS ® (eflapegrastim) on the same day as

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 16, 2020-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation of the results for preclinical studies evaluating the administration of ROLONTIS

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 3, 2020-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that Lyndah K. Dreiling , M.D., MBA, has been named Senior Vice President, Clinical Development.

HENDERSON, Nev. --(BUSINESS WIRE)--May 27, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at

BLA for ROLONTIS ® (eflapegrastim) under active FDA review - PDUFA date on October 24, 2020 ROLONTIS same day dosing study initiated Updated Poziotinib strategy implemented to include new dosing regimens Poziotinib ZENITH20 Cohort 3 fully enrolled Management to host webcast and conference call

HENDERSON, Nev. --(BUSINESS WIRE)--May 1, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2020 financial results and provide a corporate update

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 30, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced dosing of the first patient in a clinical trial to evaluate the administration of ROLONTIS on the same day as

ZENITH20 Phase 2 clinical trial amended to include new dosing regimens aimed at improving therapeutic index Management to host webcast and conference call today to review data and program strategy at 8:30 a.m. ET HENDERSON, Nev. --(BUSINESS WIRE)--Apr.

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 23, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Seth H.Z. Fischer to its Board of Directors. Mr. Fischer fills a vacancy left by Mr.

Management to host webcast and conference call to review data and program strategy at 8:30 a.m. ET on April 28, 2020 HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 21, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today

Conference call to discuss the data and strategy for the program originally scheduled for 8 a.m. ET on March 18, 2020 has been postponed HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today

Management to host webcast and conference call to review data and program strategy at 8 a.m. ET on March 18, 2020 HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at the Barclays

BLA for ROLONTIS ® (eflapegrastim) accepted for FDA review - PDUFA date on October 24, 2020 Data from poziotinib Cohort 1 of ZENITH20 accepted for podium presentation on March 18 at 11 th Annual Congress on Pulmonary and Respiratory Medicine in Amsterdam Spectrum plans to hold a conference call

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 20, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the fourth quarter and full year 2019 financial

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 6, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the

HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 26, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today reported that its pre-specified primary endpoint in its Phase 2 clinical trial evaluating poziotinib in previously

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 14, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the